As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The ...

Myriad Genetics has a 1-year low of $9.36 and a 1-year high of $29.30. The firm has a market cap of $885.70 million, a price-to-earnings ratio of -7.46 and a beta of 1.79.

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from $18.00 to $16.00 in a note issued to investors on Tuesday,Benzinga reports. The ...

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year ...

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...

Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (LSE:0K3W) from Neutral to Overweight. As of March 4, 2025, the average one-year price target for ...

Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN). Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases ...